Yeni Antibiyotikler

Yıl 2015, , 99 - 103, 01.07.2015

Manolya Acar Ayper Somer Nuran Salman

https://doi.org/10.5222/j.child.2015.099

Öz

Son yıllarda dirençli mikroorganizmalara bağlı enfeksiyon sıklığında artış gözlenmesine rağmen, yeni antibiyotik geli- şimi ile ilgili çalışmalar oldukça sınırlıdır. Bu makalede, özellikle dirençli hastane enfeksiyonlarında önemini koru- yan linezolid ve tigesiklin ile ülkemizde henüz kullanıma girmemiş olan seftarolinin farmakolojik özellikleri ve klinik endikasyonları derlenmiştir. Linezolid, oksazolidinon sınıfı antibiyotiklerin ilki olan bakteriyel protein sentez inhibitö- rü bir ajandır. Erişkin ve çocukta VRE, MRSA ve dirençli pnömokok suşları dahil, gram-pozitif bakterilere bağlı dirençli enfeksiyonların tedavisinde kullanılmaktadır. Tigesiklin, minosiklin gibi bakteriyel 30S ribozomuna bağ- lanarak etkili olur. Pseudomonas aeruginosa dışında, dirençli gram-pozitif, gram-negatif ve anaerobları kapsa- yan oldukça geniş bir spektrumu vardır. Erişkinlerde, komplike deri ve yumuşak doku enfeksiyonları ile komplike intra-abdominal enfeksiyonların tedavisinde klinik kulla- nım onayı almıştır. Seftarolin, beşinci kuşak sefalosporin grubunun üyesi olan yeni bir antimikrobiyal ajandır. Metisilin ve vankomisin dirençli Staphylococcus aureus dahil dirençli gram-pozitif mikroorganizmalara etkinliği yüksektir

Anahtar Kelimeler

Linezolid, tigesiklin, seftarolin

New Antibiotics

Öz

Despite the increase of resistant microorganism-related infections in recent years, ongoing studies for the deve- lopment of new antibiotics have been very limited. This article reviews the pharmacological properties and the clinical use of linezolid and tigecycline which are impor- tant choices for resistant nosocomial infections, in additi- on to ceftaroline, a newer drug that has not yet been in clinical use in our country. Linezolid, is the first drug of oxazolidinone class of antibiotics which inhibits bacterial protein synthesis. It has clinical indication for resistant gram-positive infections, including VRE, MRSA and resis- tant pnemococci, both in children and adults. Tigecycline binds bacterial ribosomal 30 S subunit like minocycline. It has a broad activity spectrum including resistant gram- positive, gram-negative and anaerobic bacteria other than Pseudomonas aeruginosa. It has clinical use for resistant complicated skin soft tissue and intra-abdominal infections for adults. Ceftaroline, is the newest member of 5th generation cephalosporins. It has antimicrobial acti- vity against resistant gram-positive microorganisms inc- luding methicilline- and vancomycine- resistant Staphylococcus aureus

Anahtar Kelimeler

Linezolid, tigecycline, ceftaroline

Kaynakça

• Tan TQ. Update on the use of linezolid a pediatric perspective. Pediatr Infect Dis J 2004;23:955-6.
• https://doi.org/10.1097/01.inf.0000142502.13252.20
• Saiman l, Goldfarb J, Kaplan SA, et al. Safety and tolerability of linezolid in children. Pediatr Infect Dis J 2003;2:193-200.
• https://doi.org/10.1097/01.inf.0000087022.58089.d8
• Harmony P, Garges and Kenneth A. Pharmacology Review: Newer Antibiotics: Linezolid. NeoReviews 2003;4:128.
• https://doi.org/10.1542/neo.4-5-e128
• Micek ST. Alternatives to vancomycin for the treat- ment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2007;45:184-90.
• https://doi.org/10.1086/519471
• Steiner M. Cochrane in context: Linezolid versus van- comycin for skin and soft tissue infections. Evid.-Based Child Health 2014;9:167-8.
• https://doi.org/10.1002/ebch.1958
• Cox H, Ford N. Linezolid for the treatment of compli- cated drugresistant tuberculosis: A systematic review and meta-analysis. Int J Tuberc Lung Dis 2012;16:447- 54.
• https://doi.org/10.5588/ijtld.11.0451
• Sotgui G, centis r, D’Ambrosio l et. al. Efficacy, safety, and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis. Eur Respir J 2012;40:1430-42.
• https://doi.org/10.1183/09031936.00022912
• Kishor K, Dhasmana n, Kamble SS, et al. Linezolid induced adverse drug reactions - An update. Curr Drug Met 2015;16:553-9.
• https://doi.org/10.2174/1389200216666151001121004
• ozkaya-Parlakay A, Kara A, celik m, et al. Early lactic acidosis associated with linezolid therapy in pae- diatric patients. Int J Antimicrob Agents 2014;44: 334-6.
• https://doi.org/10.1016/j.ijantimicag.2014.06.017
• Product Information: TYGACIL(R) intravenous injec- tion, tigecycline intravenous injection. Wyeth Pharma- ceuticals, Inc. (per FDA), Philadelphia, PA, 2013.
• livermore Dm. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005;56: 611-4.
• https://doi.org/10.1093/jac/dki291
• noskin GA. Tigecycline: a new glycylcycline for treat- ment of serious infections. Clin Infect Dis 2005;41:303- 14.
• https://doi.org/10.1086/431672
• rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother 2005;14: 12-22.
• https://doi.org/10.1179/joc.2005.17.Supplement-1.12
• Product Information: TEFLARO(R) intravenous injec- tion powder, ceftaroline fosamil intravenous injection powder. Forest Pharmaceuticals (per FDA), Parsippany, NJ, 2015.
• Friedland HD, o’neal T, Biek D, et al. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2012;56:2231-6.
• https://doi.org/10.1128/AAC.05738-11
• Dimondi VP, Drew rH, chen lF, et al. Ceftaroline fosamil for treatment of community-acquired pneumo- nia: findings from FOCUS 1 and 2 and potential role in therapy. Expert Rev Anti Infect Ther 2011;9:567-72.
• https://doi.org/10.1586/eri.11.82
• Zhanel GG, Sniezek G, Schweizer F, et al. Ceftaroline, a novel broad-spectrum çephalosporin with üctivity against meticillin-resistant Staphylococcus aureus. Drugs 2009;69:809-31.
• https://doi.org/10.2165/00003495-200969070-00003